Ajanta Pharma Ltd.

₹2,791.2

-25.6 (-0.9%)

AJANTPHARM Share Price

Pharmaceuticals & Biotechnology

As on April 2, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 34,925 Cr

P/E Ratio37.88

Dividend Yield0.5 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	2,820.18	Bearish
10-DMA	2,866.61	Bearish
20-DMA	2,932.93	Bearish
50-DMA	2,889	Bearish
100-DMA	2,767.97	Bullish
200-DMA	2,671.27	Bullish

Historical Performance

1 Year

6.6%

3 Years

130.9%

5 Years

139.5%

10 Years

200.5%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	46,481	42,087	37,426	33,410	28,897
Total Expenditure	33,886	30,368	29,594	24,117	18,911
Other Income	945	846	986	1,157	260
Operating Profit	13,540	12,565	8,819	10,450	10,245
Interest	207	72	58	102	83
Depreciation	1,441	1,354	1,308	1,253	1,161
Profit Before Tax	11,892	11,139	7,452	9,095	9,002
Consolidated Net Profit	9,204	8,162	5,880	7,127	6,539
Adjusted EPS	74	65	47	56	50

Compounded Sales Growth

10 Years:25.8

5 Years:12.4

3 Years:6.8

TTM:2

Compounded Profit Growth

10 Years:24.3

5 Years:14.5

3 Years:5.2

TTM:2.4

Stock Price CAGR

10 Years:11.6

5 Years:19.1

3 Years:31.5

TTM:6.5

Return on Equity

10 Years:31.5

5 Years:50.4

3 Years:46.7

last year:73.7

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	251	253	253	172	174
Total Reserves	37,600	35,364	33,624	32,469	29,777
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	421	408	1,774	2,850	2,745
Other Current Liabilities	4,780	3,695	6,694	3,015	2,141
Short Term Borrowings	---	---	---	---	---
Total Liabilities	48,285	45,039	47,046	41,968	41,090
Capital Work in Progress	1,763	2,565	2,095	1,529	1,082
Long Term Loans & Advances	182	144	1,348	2,365	2,307
Currents Investments	4,387	3,300	5,103	1,219	1,757
Short Term Loans and Advances	894	1,323	894	851	2,755
Total Current Assets	28,297	27,221	28,252	22,645	22,178
Total Assets	48,285	45,039	47,046	41,968	41,090
Adjusted Book Value	303	283	269	255	231

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 37.88, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a strong 3-year price CAGR of 31.5%, indicating sustained price appreciation.
The stock carries a low beta of 0.7, suggesting lower volatility than the broader market.
In the last financial year, the company reported an EBITDA of ₹13540 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹46481 million, indicating a large and established business.

Investment Calculator

Investment Amount:

₹

Investment Amount: ₹ 1000000

Current Value: ₹ 1064876.1

No. of Shares: 382 (Approx)

Performance:6.5%

P/L: ₹64876.1

NIFTY Performance: -2.3%

1 day Top Gainers